XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
14 août 2024 09h15 HE
|
XTL Biopharmaceuticals Ltd.
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private...
XTL Entered Definitive Agreement to Acquire The Social Proxy
05 juin 2024 09h15 HE
|
XTL Biopharmaceuticals Ltd.
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million...
XTL To Aquire The Social Proxy
20 mars 2024 10h15 HE
|
XTL Biopharmaceuticals Ltd.
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI companydeveloping and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a...
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
20 oct. 2023 16h00 HE
|
XTL Biopharmaceuticals Ltd.
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets...
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
20 oct. 2023 16h00 HE
|
XTL Biopharmaceuticals Ltd.
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets...